<DOC>
	<DOCNO>NCT00321932</DOCNO>
	<brief_summary>RATIONALE : Zoledronic acid , vitamin D , calcium may prevent bone loss patient undergo donor stem cell transplant . PURPOSE : This randomized phase II trial study well zoledronic acid work prevent osteoporosis patient undergo donor stem cell transplant .</brief_summary>
	<brief_title>Zoledronic Acid Preventing Osteoporosis Patients Undergoing Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate whether prophylactic administration zoledronic acid reduce severity bone mineral loss patient undergo allogeneic hematopoietic stem cell transplantation . Secondary - Determine safety zoledronic acid patient . OUTLINE : This multicenter , open-label , prospective , randomize , control study . Patients stratify accord participate center type transplant ( myeloablative v nonmyeloablative ) . Patients randomize 1 2 treatment arm . - Arm I ( control ) : Patients receive oral cholecalciferol ( vitamin D ) oral calcium day 12 month . - Arm II ( treatment ) : Patients receive vitamin D calcium arm I . Patients also receive zoledronic acid intravenously ( IV ) 15-30 minute 28 day prior stem cell transplantation 3 6 month transplantation . In arm , treatment continue absence unacceptable toxicity . After completion study treatment , patient follow periodically 12 month .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Patient age ≥18 year Undergoing allogeneic hematopoietic stem cell transplantation ( HCT ) stem cell source either myeloablative nonmyeloablative conditioning regimen Bone mineral density measure baseline pretransplant DEXA scan osteopenic range ( define Tscore 1 2.5 standard deviation ( SD ) either lumbar spine proximal femur ) Adequate renal function define : Calculated creatinine clearance ≥ 60 ml/min use CockcroftGault formula : Serum calcium ( correct ) ≤ 10.5 mg/dl Patients ( male female ) reproductive potential require use medically acceptable contraception receive zoledronic acid ( assign study drug ) . Normal dental exam within year prior study registration Informed sign consent participate study Preexisting metabolic bone disease include osteomalacia , hyperparathyroid bone disease , osteogenesis imperfecta , Paget 's disease , rickets , hypoparathyroidism . Multiple myeloma History nontraumatic vertebral compression fracture History follow endocrine disorder hyperparathyroidism , hyperthyroidism . Malabsorption syndrome include Crohn 's disease . Chronic liver disease Concomitant regular use phenytoin . Known hypersensitivity zoledronic acid ( Zometa ) biphosphonates Biphosphonate therapy within precede six month . Current active dental problem include infection teeth jawbone ( maxilla mandibular ) ; dental fixture trauma , current prior diagnosis osteonecrosis jaw ( ONJ ) , expose bone mouth , slow healing dental procedure . Recent ( within 6 week ) plan dental jaw surgery ( e.g . extraction , implant ) Not pregnant breastfeed since zoledronic acid classify Pregnancy Category C : risk pregnancy rule . A negative pregnancy test require within 7 day registration pre perimenopausal ( i.e. , last menstrual period within one year registration ) . Because know whether zoledronic acid excrete breast milk , breastfeed permit receive study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>